Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michele Trippel

Internal Medicine Lansdowne, VA Medical Doctor

NPI 1225078587 CMS profile 10365

19420 Golf Vista Plaza, Suite 130, Lansdowne, VA 20176

Open in the dashboard

General payments

$7,028

349 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michele Trippel of Lansdowne, VA is reported in the CMS Open Payments database as having received $7,028 across 349 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,091 38
2024 General $1,079 48
2023 General $1,005 52
2022 General $851 48
2021 General $1,134 60
2020 General $878 46
2019 General $990 57

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michele Trippel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Michele Trippel were reported at $1,091. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Michele Trippel Internal Medicine median Middle half National median
2019 $990 $159 $48–$570 $163
2020 $878 $119 $33–$402 $114
2021 $1,134 $135 $37–$521 $132
2022 $851 $141 $42–$496 $149
2023 $1,005 $149 $45–$519 $160
2024 $1,079 $154 $47–$537 $164
2025 $1,091 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,437 116 payments
  2. AbbVie, Inc. $920 50 payments
  3. Lilly USA, LLC $489 26 payments
  4. AstraZeneca Pharmaceuticals LP $368 22 payments
  5. Amarin Pharma Inc. $268 13 payments
  6. Amneal Pharmaceuticals LLC $237 11 payments
  7. GlaxoSmithKline, LLC. $236 7 payments
  8. Pfizer Inc. $232 12 payments
  9. Sanofi-Aventis U.S. LLC $211 8 payments
  10. Eisai Inc. $198 8 payments
  11. Other $1,431 76 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,962 346 payments
  2. Education $66 3 payments
Products named General payments · program years 2019–2025
  1. Ozempic $1,805 96 payments
  2. RYBELSUS $1,366 74 payments
  3. Wegovy $515 13 payments
  4. SYNTHROID $304 17 payments
  5. VRAYLAR $261 15 payments
  6. UNITHROID $237 11 payments
  7. MOUNJARO $231 12 payments
  8. Vascepa $225 11 payments
  9. UBRELVY $215 11 payments
  10. JARDIANCE $211 11 payments
  11. Other $4,204 210 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

2,396

Median for Internal Medicine: 777

Drug cost

$149,920

Median for Internal Medicine: $73,373

Branded share of claims

21.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 48 $55,494
Januvia Sitagliptin Phosphate Brand 13 $15,945
Eliquis Apixaban Brand 22 $12,855
Synthroid Levothyroxine Sodium Brand 158 $12,061
Jardiance Empagliflozin Brand 18 $10,894
Cymbalta Duloxetine Hcl Brand 20 $6,559
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 18 $6,477
Humalog Kwikpen U-100 Insulin Lispro Brand 19 $4,589
Rosuvastatin Calcium Generic 242 $3,425
Olmesartan Medoxomil Generic 63 $2,293

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$63,418

Medicare's payments for the services billed

Medicare patients

247

Average age 76

Services billed

824

167 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 47%
Diabetes 22%
Ischemic heart disease 19%
Cancer 19%
Osteoporosis 17%
Atrial fibrillation 16%
Depression 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AREXVY
  • GlaxoSmithKline, LLC. $148
$148 — —
RYBELSUS
  • Novo Nordisk Inc $147
$147 — —
Ozempic
  • Novo Nordisk Inc $147
$147 48 —
Wegovy
  • Novo Nordisk Inc $98
$98 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

349 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record